ALZN News & Events

Alzamend Neuro will have a poster presentation at the Military Health System Research Symposium, being held from August 4-7, 2025, in Orlando, Florida. Title: Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate: Summary: The current study is designed to quantitate differences in lithium brain-to-plasma exposure in PTSD subjects between AL001 and lithium carbonate for the purpose of contributing to a composite database of analogously studied brain-plasma assessments that include data from healthy subjects and multiple additional neurodegenerative, neurological and neuropsychiatric disorders. Currently, AL001 is targeted for treatment of Alzheimer's, BD type 1, MDD and PTSD. It's anticipated that this study design may help target appropriate AL001 lithium systemic dosing for these indications in future studies. Using this study design, comparable target organ lithium concentrations may be quantitated between AL001 and lithium carbonate and, by equivalence inference, lithium citrate solution and syrup.

Alzamend Neuro reported its financial results for the year ended April 30, 2025, which were disclosed on an annual report on Form 10-K filed on July 22, 2025, with the Securities and Exchange Commission. Alzamend has strengthened its financial position, reflecting a strategic focus on fiscal prudence and effective capital management. Key financial highlights include: Net cash provided by financing activities of $10.4 million for the year ended April 30, 2025; Stockholder equity of $3.9 million at April 30, 2025, compared to a stockholder deficit of $2.6 million at April 30, 2024; Cash of $3.9 million at April 30, 2025, compared to $0.4 million at April 30, 2024; and Total liabilities of $0.6 million at April 30, 2025, compared to $3.2 million at April 30, 2024. "The successful completion of this Financing, months ahead of schedule, reflects confidence in our mission and strong belief in our vision," said Stephan Jackman, Chief Executive Officer of Alzamend. "The capital raised will be used to support the five Phase II clinical trials of AL001 "Lithium in Brain" Studies in partnership with Massachusetts General Hospital and Harvard Medical School."

Alzamend Neuro has completed the final closing of its $5 million private placement. As previously reported, on February 28, 2025, Alzamend entered into a Securities Purchase & Exchange Agreement with a sophisticated investor, pursuant to which Alzamend agreed to sell to the Investor up to 500 shares of Series C Convertible Preferred Stock and warrants to purchase shares of Alzamend's common stock for a total purchase price of up to $5 million, less a five percent discount in seven monthly tranche closing, starting in April 2025, with the Investor having the ability, in its sole discretion, to purchase Preferred Stock prior to the dates set for each Tranche Closing. On Friday, June 13, 2025, the Investor purchased the remaining available shares of Preferred Stock in the Financing, months ahead of the originally scheduled final Tranche Closing in October 2025. With $5 million in gross proceeds from this Financing received, Alzamend's financial position is significantly increased, and Alzamend would receive additional proceeds should the Investor exercise the Warrants. The capital raised will be used to support the five Phase II clinical trials of AL001 "Lithium in Brain" Studies at Massachusetts General Hospital. The first trial, in healthy human subjects, was initiated in May 2025 and Alzamend expects to present topline data from this study by the end of 2025. The second trial, for treatment of patients with BD, is expected to commence in the third quarter of 2025. The remaining three trials, for treatment of patients with Alzheimer's, MDD and PTSD are each expected to commence in the fourth quarter of 2025.

Alzamend Neuro announced the dosing of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.